Amarin (AMRN) Shakes Off Weakness, Sees Notable Upside
Get Alerts AMRN Hot Sheet
Join SI Premium – FREE
Shares of Amarin Corporation plc (NASDAQ: AMRN) are moving higher early Thursday, erasing a good chuck of the losses from earlier in the week after another NCE delay and some negative press about fish oil pills.
Many analysts have still been positive on the stock, and eventually NCE approval, despite the delay. One analyst suggested the FDA may be waiting for additional granted patents in order to legally support a decision to grant NCE and to fend off potential complaints by GlaxoSmithKline, the marketer of Lovaza.
Shares are up 4.6 percent ot $13.94 in early action.
Many analysts have still been positive on the stock, and eventually NCE approval, despite the delay. One analyst suggested the FDA may be waiting for additional granted patents in order to legally support a decision to grant NCE and to fend off potential complaints by GlaxoSmithKline, the marketer of Lovaza.
Shares are up 4.6 percent ot $13.94 in early action.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Equity fund flows positive for fifth month, market broadening expected - Barclays
- Roivant Sciences (ROIV) to Join S&P MidCap 400; Sunrun (RUN) to Join S&P SmallCap 600
- Stocks subdued, yen in focus, with inflation data on tap
Create E-mail Alert Related Categories
Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!